An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Inclusion Criteria:

1. Subject voluntarily gives informed consent to participate in the study.

2. The subject participated in study RIN-PH-201, remained on study drug, was compliant
with RIN-PH-201 study procedures or was enrolled in study RIN-PH-201 at the time that
the study was discontinued by the sponsor.

3. Females of reproductive potential must be non-pregnant (as confirmed by a urine
pregnancy test at Baseline) and non-lactating, and will:

- Either abstain from intercourse (when it is in line with their preferred and
usual lifestyle), or

- Use two medically acceptable, highly-effective forms of contraception for the
duration of study, and at least 30 days after discontinuing study drug.

4. Males must use a condom for the duration of treatment and for at least 48 hours after
discontinuing study drug.

Exclusion Criteria:

1. The subject is pregnant or lactating.

2. The subject was prematurely discontinued from study RIN-PH-201.

3. The subject developed a concurrent illness or condition during the conduct of
RIN-PH-201 which, in the opinion of the Investigator, would represent a risk to
overall health if they enrolled in this study.